Myovant Sciences Stock Price - MYOV

12.75
0.01 (0.08%)
Upgrade to Real-Time
Afterhours (Closed)
12.74
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Level 1 Starter
Monthly Subscription
for only
$15.87
VAT not included
Company Name Stock Ticker Symbol Market Type
Myovant Sciences Ltd MYOV NYSE Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.06 -0.47% 12.74 12.47 12.87 12.81 12.80 20:00:00
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
3,312 383,251 $ 12.72 $ 4,873,535 825,312 4.14 - 19.58
Last Trade Time Type Quantity Stock Price Currency
19:40:27 formt 800 $ 12.75 USD

Myovant Sciences Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.14B 89.79M 88.22M $ - $ - -3.37 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
3.02M $ - 0.00% 9.00 1.80%

more financials information »

Myovant Sciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical MYOV Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week11.8913.5011.7912.43727,6710.857.15%
1 Month12.3613.9910.9912.24707,0770.383.07%
3 Months9.3013.995.949.88890,1543.4436.99%
6 Months12.3619.585.9413.021,101,9720.383.07%
1 Year12.8419.584.1412.041,087,505-0.10-0.78%
3 Years11.8127.454.1412.76415,3930.937.87%
5 Years15.0027.454.1412.72370,377-2.26-15.07%

Myovant Sciences Description

Myovant Sciences Ltd is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing therapies for women's health diseases and other endocrine-related disorders. Its product candidate is relugolix, which is an oral, once-daily, gonadotropin-releasing hormone (GnRH) receptor antagonist. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, for the treatment of female infertility as part of assisted reproduction.


Your Recent History
NYSE
MYOV
Myovant Sc..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.